Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bush, K. A.
Right arrow Articles by Walker, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bush, K. A.
Right arrow Articles by Walker, J. S.
Related Collections
Right arrow Experimental Arthritis
Right arrow Immunogenetics
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 1013-1021
© 2001 British Society for Rheumatology

Original Papers

The {kappa}-opioid agonist, asimadoline, alters cytokine gene expression in adjuvant arthritis

K. A. Bush, B. W. Kirkham1 and J. S. Walker

School of Physiology and Pharmacology, University of New South Wales and
1 Department of Rheumatology, St George Hospital, New South Wales, Australia

Objective. We have previously found that the {kappa}-opioid agonist, asimadoline, attenuates adjuvant arthritis in a dose-dependent, antagonist-reversible manner. To elucidate possible mechanisms, we investigated the effects of asimadoline (5 mg/kg/day i.p.) or vehicle on in vivo cytokine expression and T-cell recruitment in adjuvant arthritis.

Methods. Arthritis severity was assessed every 3–4 days for 21 days. Rats were killed on days 0, 13 and 21 post-induction and synovial membrane and inguinal lymph nodes were removed for mRNA extraction. Changes in cytokine mRNA expression were measured using reverse transcription–polymerase chain reaction (RT–PCR) and densitometry. T cells in joints were quantified by immunohistochemistry.

Results. Asimadoline significantly decreased arthritis severity at day 13, with a concomitant decrease in synovial membrane expression of cytokines interleukin-17 and transforming growth factor-ß (TGF-ß) mRNA at day 13, and no change in T cell numbers in the joints of arthritic rats. By contrast, in the inguinal lymph nodes, expression of tumour necrosis factor was increased at day 13 and TGF-ß mRNA was increased throughout.

Conclusion. An altered balance, therefore, in the pro- and anti-inflammatory effects of TGF-ß by asimadoline might explain its striking anti-arthritic actions.

KEY WORDS: Cytokines, Opioids, Asimadoline, Adjuvant arthritis, {kappa}-Opioid agonist, Inflammation.

Correspondence to: J. Walker, School of Physiology and Pharmacology, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia, 2052


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.